01/07/2022 Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
The Ministry of Health’s Drug Advisory Committee has recommended:
- Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with NVAF and:
- CHA2DS2-VASc score of 1 or more for men; and
- CHA2DS2-VASc score of 2 or more for women.
Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral stenosis), or patients with prosthetic heart valves.
Subsidy status
RRivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
RApixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL).
NRSDL subsidy or MAF assistance do not apply to any strengths of dabigatran.